We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic
function and immune cells among participants in a previously reported randomized …

Aims/hypothesis The long-term effects of successful immune therapies for treatment of type 1
diabetes have not been well studied. The Autoimmunity-Blocking Antibody for Tolerance …

Aims/hypothesis Type 1 diabetes results from a chronic autoimmune process continuing for
years after presentation. We tested whether treatment with teplizumab (a Fc receptor non …

Background Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved
by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) …

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not
all subjects respond, and the duration of response is limited. Our aim was to determine …

OBJECTIVE In November 2022, teplizumab-mzwv became the first drug approved to delay
the onset of stage 3 type 1 diabetes in adults and children age≥ 8 years with stage 2 type 1 …

Background Type 1 diabetes is a chronic autoimmune disease that leads to destruction of
insulin-producing beta cells and dependence on exogenous insulin for survival. Some …

Biologic treatment of type 1 diabetes (T1D) typically results in transient stabilization of C-
peptide levels (a surrogate for endogenous insulin secretion) in some patients, followed by …

Anti-CD3 mAbs may prolong β cell function up to 2 years in patients with new onset Type 1
diabetes (T1DM). A randomized open label trial of anti-CD3 mAb, Teplizumab, in T1DM was …

Protégé was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study
of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline …